fda compounding glp-1 enforcement news today National Minority Quality Forum Launches “Health Not Hype” Campaign During Obesity Care Week to Warn Patients About Risks of Compounded Drugs FDA Warns 25 Firms Over

24 0.8 pmol/mg protein

Clinical trials show that discontinuing GLP-1 therapy leads to weight regain in approximately 70% of patients within one year, underscoring why these medications function best as long-term treatment rather than temporary interventions

doi: 10.1038/ncpendmet0017 [DOI] [PubMed] [Google Scholar] 13

Target a minimum of 0.8 grams of protein per pound of goal body weight

Less common long-term risks include gallbladder disease and, rarely, pancreatitis

Before starting GLP-1 therapy, discuss your personal and family history of easy bruising, bleeding gums, heavy menstrual bleeding, or blood clotting disorders with your provider